Zirconium-89 Labeled Antibodies: a New Tool for Molecular Imaging in Cancer Patients

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Jul 4

PMID 24991539

Citations 48

Authors

Floor C J van de Watering

Mark Rijpkema

Lars Perk

Ulrich Brinkmann

Wim J G Oyen

Otto C Boerman

Affiliations

Soon will be listed here.

Abstract

Antibody based positron emission tomography (immuno-PET) imaging is of increasing importance to visualize and characterize tumor lesions. Additionally, it can be used to identify patients who may benefit from a particular therapy and monitor the therapy outcome. In recent years the field is focused on (89)Zr, a radiometal with near ideal physical and chemical properties for immuno-PET. In this review we will discuss the production of (89)Zr, the bioconjugation strategies, and applications in (pre-)clinical studies of (89)Zr-based immuno-PET in oncology. To date, (89)Zr-based PET imaging has been investigated in a wide variety of cancer-related targets. Moreover, clinical studies have shown the feasibility for (89)Zr-based immuno-PET to predict and monitor treatment, which could be used to tailor treatment for the individual patient. Further research should be directed towards the development of standardized and robust conjugation methods and improved chelators to minimize the amount of released Zr(4+) from the antibodies. Additionally, further validation of the imaging method is required. The ongoing development of new (89)Zr-labeled antibodies directed against novel tumor targets is expected to expand applications of (89)Zr-labeled immuno-PET to a valuable method in the medical imaging.

Citing Articles

[Cu]Cu-NOTA-Trastuzumab and [Zr]Zr-DFO-Trastuzumab in Xenografts with Varied HER2 Expression.

Simo C, Shmuel S, Vanover A, Pereira P Mol Pharm. 2024; 21(12):6311-6322.

PMID: 39471823 PMC: 11611601. DOI: 10.1021/acs.molpharmaceut.4c00777.

Development of Mn Labeled Trastuzumab for Extended Time Point PET Imaging of HER2.

Omweri J, Saini S, Houson H, Tekin V, Pyles J, Parker C Mol Imaging Biol. 2024; 26(5):858-868.

PMID: 39192059 PMC: 11436409. DOI: 10.1007/s11307-024-01948-4.

Preparation of a Zirconium-89 Labeled Clickable DOTA Complex and Its Antibody Conjugate.

Basuli F, Vasalatiy O, Shi J, Lane K, Escorcia F, Swenson R Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675440 PMC: 11053460. DOI: 10.3390/ph17040480.

Decoding Tumor Angiogenesis for Therapeutic Advancements: Mechanistic Insights.

Kaur G, Roy B Biomedicines. 2024; 12(4).

PMID: 38672182 PMC: 11048662. DOI: 10.3390/biomedicines12040827.

Noninvasive PET imaging of tumor PD-L1 expression with Cu-labeled Durvalumab.

Malih S, Lin W, Tang Z, DeLuca M, Engle J, Alirezapour B Am J Nucl Med Mol Imaging. 2024; 14(1):31-40.

PMID: 38500749 PMC: 10944374.

References

Riethdorf S, Reimers N, Assmann V, Kornfeld J, Terracciano L, Sauter G . High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006; 119(8):1800-10. DOI: 10.1002/ijc.22062. View

Deri M, Zeglis B, Francesconi L, Lewis J . PET imaging with ⁸⁹Zr: from radiochemistry to the clinic. Nucl Med Biol. 2012; 40(1):3-14. PMC: 3517725. DOI: 10.1016/j.nucmedbio.2012.08.004. View

Dijkers E, Munnink T, Kosterink J, Brouwers A, Jager P, de Jong J . Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010; 87(5):586-92. DOI: 10.1038/clpt.2010.12. View

Chan J, Stuart K, Earle C, Clark J, Bhargava P, Miksad R . Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012; 30(24):2963-8. PMC: 4874232. DOI: 10.1200/JCO.2011.40.3147. View

Yeh H, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C . Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A. 2011; 108(4):1603-8. PMC: 3029752. DOI: 10.1073/pnas.1010744108. View

Jones C, Taylor M, McWilliams B . The role of cetuximab as first-line treatment of colorectal liver metastases. HPB (Oxford). 2012; 15(1):11-7. PMC: 3533707. DOI: 10.1111/j.1477-2574.2012.00591.x. View

Vugts D, Vervoort A, Stigter-van Walsum M, Visser G, Robillard M, Versteegen R . Synthesis of phosphine and antibody-azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach. Bioconjug Chem. 2011; 22(10):2072-81. DOI: 10.1021/bc200298v. View

Sugyo A, Tsuji A, Sudo H, Nagatsu K, Koizumi M, Ukai Y . Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer. PLoS One. 2013; 8(4):e61230. PMC: 3618331. DOI: 10.1371/journal.pone.0061230. View

Schweizer M, Carducci M . From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J. 2013; 19(1):99-106. DOI: 10.1097/PPO.0b013e31827e0b86. View

10.

Oude Munnink T, de Vries E, Vedelaar S, Timmer-Bosscha H, Schroder C, Brouwers A . Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts. Mol Pharm. 2012; 9(11):2995-3002. DOI: 10.1021/mp3002182. View

11.

Gaykema S, Brouwers A, Lub-de Hooge M, Pleijhuis R, Timmer-Bosscha H, Pot L . 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013; 54(7):1014-8. DOI: 10.2967/jnumed.112.117218. View

12.

Nagengast W, de Korte M, Oude Munnink T, Timmer-Bosscha H, den Dunnen W, Hollema H . 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med. 2010; 51(5):761-7. DOI: 10.2967/jnumed.109.071043. View

13.

Gross M, Shazer R, Agus D . Targeting the HER-kinase axis in cancer. Semin Oncol. 2004; 31(1 Suppl 3):9-20. DOI: 10.1053/j.seminoncol.2004.01.005. View

14.

Chang A, De Silva R, Lapi S . Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging. 2013; 12(1):17-27. PMC: 4329987. View

15.

Holland J, Divilov V, Bander N, Smith-Jones P, Larson S, Lewis J . 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010; 51(8):1293-300. PMC: 2998794. DOI: 10.2967/jnumed.110.076174. View

16.

Verel I, Visser G, Boellaard R, Boerman O, van Eerd J, Snow G . Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003; 44(10):1663-70. View

17.

Bruno R, Washington C, Lu J, Lieberman G, Banken L, Klein P . Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005; 56(4):361-9. DOI: 10.1007/s00280-005-1026-z. View

18.

Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K . Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate. 2012; 73(8):835-41. DOI: 10.1002/pros.22627. View

19.

Perk L, Stigter-van Walsum M, Visser G, Kloet R, Vosjan M, Leemans C . Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008; 35(10):1857-67. DOI: 10.1007/s00259-008-0774-5. View

20.

Sham J, Kievit F, Grierson J, Miyaoka R, Yeh M, Zhang M . Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med. 2014; 55(5):799-804. PMC: 4116087. DOI: 10.2967/jnumed.113.132118. View